MRTX News and Press, Mirati Therapeutics Inc. From 12/31/23

2023-12-31 02:49:47 ET Summary Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allowing it to expand its drug portfolio and product candi...

2023-12-26 09:29:27 ET More on Amgen Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Amgen upgraded by BMO on underappreciated opportunity in o...

2023-12-25 05:42:51 ET Summary Mirati Therapeutics is a biotech company specializing in oncology therapies, with its star product being adagrasib for treating lung cancer. Bristol Myers Squibb is set to acquire Mirati Therapeutics for $4.8 billion, with shareholders receiving a Co...

2023-12-23 04:24:25 ET Summary Bristol Myers Squibb is resorting to larger M&A deals to drive new product sales and combat the challenges it faces with the loss of exclusivity of its top-selling drug Revlimid. The company's 2023 outlook is tough, with stagnation and a decline ...

2023-12-19 15:00:00 ET Summary Bristol Meyers Squibb's stock is down nearly 15% over the past 3 years and currently trades at a price to earnings of less than 15x, indicating it is undervalued. BMY recently announced a deal worth $8.4 billion and another deal to acquire a biotech ...

2023-12-19 07:46:36 ET More on Mirati Therapeutics Mirati Therapeutics: Anatomy Of A Long Simmering Buyout Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Mirati lung cancer therapy endorsed in EU Bristol-Myers was only firm that...

2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-29 10:45:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – November 29, 2023 – USA News Group –  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the ri...

2023-11-24 06:48:01 ET More on Innovent Biologics Historical earnings data for Innovent Biologics Financial information for Innovent Biologics Historical earnings data for Innovent Biologics, Inc. Financial information for Innovent Biologics, Inc. For...